HIC1 modulates prostate cancer progression by epigenetic modification

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1400-1410

  Zheng, Jianghua ^a,b   Weng, Jinglong ^a   Sun, Xueqing ^a   Hao, Mingang ^a   Ding, Tao ^c   Xiong, Dan ^a   Wang, Xiumin ^a   Zhu, Yu ^d   Xiao, Gang ^a   Cheng, Guangcun ^a   Zhao, Meizhong ^d   Zhang, Jian ^e   Wang, Jianhua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^e GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CXCR7 GENE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HIC1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, CXCR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875145398     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2888     Document Type: Article

References (32)

1. BrawleyOW.Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
2. Wang Y, Zhou Z, Tian Y, Shao Q, Chen S, Hong BF, et al. Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age. Zhonghua Yi Xue Za Zhi 2009; 89:1681-83.
3. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, CaveneeWK, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995;1:570-7.
4. Morton RA Jr, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB. Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 1996;156:512-6.
5. Fujii H, Biel MA, Zhou W, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 1998;16:2159-64.
6. Kanai Y, Ushijima S, Ochiai A, Eguchi K, Hui A, Hirohashi S. DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis. Cancer Lett 1998;122:135-41.
7. Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999;29:703-9.
8. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123:437-48.
9. Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009;11:763-70.
10. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, et al. Epigenetic and genetic loss of Hic1 function accentuates the roleof p53 in tumorigenesis. Cancer Cell 2004;6:387-98.
11. Carter MG, Johns MA, Zeng X, Zhou L, Zink MC, Mankowski JL, et al. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet 2000;9:413-9.
12. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003;33:197-202.
13. Fleuriel C, Touka M, Boulay G,Guérardel C,Rood BR, Leprince D. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 2009;41:26-33.
14. Parrella P, Scintu M, Prencipe M, Poeta ML, Gallo AP, Rabitti C, et al. HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast. Cancer Lett 2005;222:75-81.
15. Zawlik I, Zakrzewska M, Witusik M, Golanska E, Kulczycka-Wojdala D, Szybka M, et al. KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural stem cells. Cancer Genet Cytogenet 2006;170:24-28.
16. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-20.
17. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997;57:1678-81.
18. Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Guérardel C, et al. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem 2009;284: 20927-35.
19. Ke Z, Lin H, Fan Z, Cai TQ, Kaplan RA, Ma C, et al. MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int J Cancer 2006;119:8-16.
20. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
21. Wang J, Shiozawa Y, Wang J, WangY, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283:4283-94.
22. Hao M, Zheng J, Hou K, Wang J, Chen X, Lu X, et al. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 2012;84:204-14.
23. Briggs KJ, Corcoran-Schwartz IM, Zhang W, Harcke T, Devereux WL, Baylin SB, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev 2008;22: 770-85.
24. Zheng J, Xiong D, Sun X, Wang J, Hao M, Ding T, et al. Signification of hypermethylated in cancer 1 (HIC1) as tumor suppressor gene in tumor progression. Cancer Microenviron 2012;5:285-93.
25. Christman JK. 5-Azacytidine and 5-aza-20-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
26. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13.
27. Raggo C, Ruhl R, McAllister S, Koon H, Dezube BJ, Fr€uh K, et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 2005;65: 5084-95.
28. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007;104:15735-40.
29. Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012;31:4750-8.
30. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010;29:709-22.
31. Stankovic-Valentin N, Deltour S, Seeler J, Pinte S, Vergoten G, Guérardel C, et al. An acetylation/deacetylation-SUMO ylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol 2007;27:2661-75.
32. Van Rechem C, Boulay G, Pinte S, Stankovic-Valentin N, Guérardel C, Leprince D. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 2010;30: 4045-59.